Probiotics-based Anticancer Immunity In Lymphomas

The gut microbiome can play an important role in maintaining homeostasis in the human body. An imbalance in the gut microbiome can lead to pro-inflammatory immune responses and the initiation of disease processes, including cancer. Lymphocytes play a significant role in the reaction to bacterial colonization, mainly by prompting a safe reaction to initiation. Most immunologically inhabitant cells are continually signaled by dendritic cells or other antigen-presenting cells that collect intestinal samples. Therefore, the microbiota is a pivotal contributor to developing lymphoma, and specific changes to microbiota composition could help prevent the risk. Microbial morphology can affect and control humanoids. The difference in the composition of these microbes is associated with tumor development. Moreover, with the increased exploration and knowledge of the connection between human microbiota and carcinogenesis, the use of these findings to predict, prevent, or diagnose lymphomas has attracted great attention. Probiotics have gained increasing medical significance due to their beneficial effect on the human body, which has been linked to the prevention and support of the treatment of many chronic diseases, including cancer, in the absence of side effects. Chemotherapy and immunotherapy are extensively used for the treatment of lymphomas. But these treatments have various side effects. There is much evidence that probiotics can help in preventing cancer and support anticancer therapy. This chapter presents the latest advances in research into the effectiveness of probiotics in the prevention and treatment support of lymphoma. In addition, the chapter also describes the potential mechanisms of probiotic chemoprevention and the advisability of using probiotics in the prevention of lymphoma. 

Keywords: B and T cell lymphoma, Chemotherapy, Immunotherapy, Immune checkpoint inhibitors (ICIs), Lymphocytes, Microbiota, Probiotics.